CANbridge Files for Approval of Breast Cancer Drug in China

CANbridge Pharma of Beijing has filed a New Drug Application in China for Nerlynx® (neratinib) as an adjuvant treatment in patients with early-stage HER2-positive breast cancer, following adjuvant Herceptin therapy. China’s National Medical Products Administration (NMPA) has accepted the filing. CANbridge in-licensed Greater China rights to Nerlynx from Puma Biotech (NSDQ: PBYI) in January 2018. In the US, Nerlynx was approved for the same indication in July 2017. CANbridge also intends to test Nerlynx in patients with HER2-positive gastric cancer. More details....

Share this with colleagues:

Original Article: CANbridge Files for Approval of Breast Cancer Drug in China

More From BioPortfolio on "CANbridge Files for Approval of Breast Cancer Drug in China"